The Future of Cord Blood Derived Cell Therapies

Saturday, November 11, 2017
10:00 a.m. – 11:00 a.m.

Speaker
John E. Wagner MD

Session Objectives
At the conclusion of this session, attendees will be able to:

1. List the advantages and disadvantages of cord blood hematopoietic cell transplantation.
2. Describe the role of CD34 expansion in cord blood transplantation.
3. State the future of umbilical cord blood - derived cell therapies.

Conflict of Interest/Financial Disclosure
The planners and speaker(s) have disclosed the following financial relationships and/or conflicts of interest:

<table>
<thead>
<tr>
<th>Name</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Del Steckler, RN, BSN, MMA</td>
<td>None</td>
</tr>
<tr>
<td>John E. Wagner, MD</td>
<td>Novartis – Contract</td>
</tr>
<tr>
<td>Merry Duffy</td>
<td>None</td>
</tr>
</tbody>
</table>